文献速递神经肌肉病

海藻糖治疗肌萎缩侧索硬化的安全性与疗效:HEALEY ALS平台试验

Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial.
PubMed 文献 · Lancet Neurol · 2025-01-01

HEALEY ALS平台试验是一项适应性2/3期随机双盲安慰剂对照研究,在美国60个中心纳入171例ALS患者,其中161例符合标准并随机分配至海藻糖组(120例)或方案内安慰剂组(41例),另加入其他方案安慰剂组164例(共205例安慰剂)。海藻糖组严重不良事件发生率16%,高于方案内安慰剂组的7%。结论:海藻糖耐受性良好,但未显示延缓ALS疾病进展的疗效。

要点

  • 海藻糖组严重不良事件发生率16%,高于方案内安慰剂组的7%,但无治疗相关死亡。
  • 次要临床或生物标志物指标均未见统计学获益,提示该剂量海藻糖可能无效。

核心结论

  • 海藻糖在ALS患者中耐受性良好,但与安慰剂相比未显示延缓疾病进展的统计学证据。

研究设计与样本

  • HEALEY ALS平台试验为永久性、适应性2/3期随机双盲多方案试验,在美国60个中心开展。
  • 主要终点为24周ALSFRS-R变化率与生存的贝叶斯共享参数模型复合指标,按意向性分析。

主要发现

  • 海藻糖组严重不良事件发生19例(16%),方案内安慰剂组3例(7%);导致提前终止分别为14例(12%) vs 1例(2%)。
  • 海藻糖组发生7例致命性治疗中出现的不良事件,方案内安慰剂组0例;无死亡被认为与试验药物相关,最常见死因为呼吸衰竭。

临床怎么用

  • 该剂量海藻糖不推荐用于ALS治疗,临床决策应基于现有循证治疗。

局限性

  • 原文未报告预设无效性停止规则的具体阈值及期中分析结果细节。
  • 原文未报告次要临床或生物标志物指标的具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trehalose is a disaccharide that activates autophagy pathways in animal models of neurodegenerative diseases, with the potential to catalyse clearance of toxic, misfolded proteins in motor neurons and slow disease progression in amyotrophic lateral sclerosis (ALS). We aimed to evaluate the safety and efficacy of trehalose in individuals with ALS. METHODS: The HEALEY ALS Platform Trial is a perpetual, adaptive, phase 2/3, randomised, double-blind, multi-regimen trial conducted at 60 geographically diverse sites in the USA. In the current regimen, adults with clinically possible, probable, laboratory-supported probable, or definite ALS, defined by the revised El Escorial criteria, were randomly allocated (3:1), stratified by use of edaravone and riluzole, to receive trehalose 0·75 g per kg intravenously weekly over 24 weeks, or matching placebo. The primary outcome was a composite of the relative rate of disease progression, as measured by the Revised ALS Functional Rating Scale (ALSFRS-R), and survival over 24 weeks, estimated in a Bayesian shared-parameter model. The study included prespecified stopping rules for futility; interim analyses occurred every 12 weeks. The primary outcome was analysed according to the intention-to-treat principle in all participants in the trehalose group, the placebo group within the regimen, and placebo groups from other contributing regimens; the safety analysis population was comprised of all participants who initiated treatment. This study is registered with ClinicalTrials.gov, NCT05136885. FINDINGS: Between Feb 21, 2022, and Feb 17, 2023, 1021 participants were screened for the platform trial and 171 were assigned to the trehalose regimen. Of these, 161 participants met eligibility criteria, with 120 randomly allocated to trehalose and 41 to regimen-specific placebo. 164 participants randomly allocated to placebo in other regimens were added for analysis (totalling 205 placebo recipients). The disease rate ratio for change in ALSFRS-R and survival was 0·87 (95% credible interval 0·665-1·102, posterior probability of superiority 0·877). Serious adverse events occurred in 19 (16%) participants in the trehalose group and three (7%) participants in the regimen-only placebo group, leading to premature discontinuations in 14 (12%) versus one (2%), respectively. Fatal treatment-emergent adverse events occurred in seven participants in the trehalose group and none in the regimen-only placebo group. No death was considered related to the trial drug. The most common cause of death was respiratory failure, consistent with the natural history of ALS. INTERPRETATION: Trehalose was well tolerated but there was no evidence to suggest a difference in ALS disease progression compared with placebo in this study. No statistical benefit was seen in secondary clinical or biomarker measures, suggesting that trehalose at this dosage is unlikely to be efficacious for treatment of ALS. FUNDING: AMG Charitable Foundation, Tackle ALS, the ALS Association, ALS Finding a Cure, the Muscular Dystrophy Association, ALS ONE, the Arthur M Blank Family Foundation, I AM ALS, Tambourine ALS Collaborative, and other community fundraising initiatives and donors. Study drug and partial regimen-related funding was provided by Seelos.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2025. PMID: 40409314. doi:10.1016/S1474-4422(25)00173-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。